F

Fullerton Neurology and Headache Center | Fullerton, CA

Research site

(Unclaimed)

Location

100 LAGUNA RD, FULLERTON, California, United States of America

Site insights

Top conditions

Top treatments

Ocrelizumab

Gantenerumab

Fenebrutinib

Galcanezumab

AR1001

Cladribine

EHP-101

LY3303560

TRx0237

Semagludtide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 18 total trials

A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease.Participants will either get sem...

Active, not recruiting

Early Alzheimer's Disease

Drug: Placebo (semaglutide)

Drug: Semagludtide

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis (FENtrepid)

A study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Scleros...

Active, not recruiting

Multiple Sclerosis, Primary Progressive

Drug: Placebo matched to ocrelizumab

Drug: Placebo matched to fenebrutinib

A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS) (FENopta)

This is a study evaluating the effect of fenebrutinib on brain magnetic resonance imaging (MRI) in participants with RMS. The safety and pharmacokine...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo

Drug: Fenebrutinib

Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzheimer's Disease (Polaris-AD)

This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to e...

Enrolling

Alzheimer Disease

Drug: Placebo

Drug: AR1001